Mariangela Palazzo

Ms. Mariangela Palazzo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Life
Verified
Journal Article
Open access
PDF file
Francesca GoriniFrancesca Gorini
Francesca Gorini
Alessandro TonacciAlessandro Tonacci
Alessandro Tonacci
MPMariangela Palazzo
Mariangela Palazzo
Andrea BorghiniAndrea Borghini
Andrea Borghini
Despite decades of interventions targeting modifiable risk factors to reduce the burden of cardiovascular disease, ischemic heart disease (IHD) remains the leading cause of mortality and the second leading cause of disability-adjusted life-years worldwide. Growing evidence suggests that phthalates–plasticizers widely used in consumer products, cosmetics, and medical devices, and therefore ubiquitous across environmental media, may contribute to IHD development. Epidemiological studies have reported associations between phthalate exposure and multiple markers of atherosclerosis, the pathological hallmark of IHD, with or without mediation by traditional cardiovascular risk factors. Experimental models support these findings, showing that phthalates can induce oxidative stress, mitochondrial dysfunction, apoptosis, lipid accumulation, and epigenetic alterations, all of which promote endothelial damage and atherogenesis. In this review, we synthesize current epidemiological findings linking phthalate exposure to IHD, describe the main cellular and molecular mechanisms involved, and outline research gaps and regulatory perspectives. We also discuss how novel analytical frameworks—including artificial intelligence—may enhance the integration of environmental, clinical, and molecular data to advance risk prediction and prevention strategies.

27 April 2026 in Toxics
Verified
Journal Article
Open access
PDF file
MPMariangela Palazzo
Mariangela Palazzo
Andrea BorghiniAndrea Borghini
Andrea Borghini
Elisa BustaffaElisa Bustaffa
Elisa Bustaffa
SBSilvia Baldacci
Silvia Baldacci
Francesca GoriniFrancesca Gorini
Francesca Gorini
FMFabrizio Minichilli
Fabrizio Minichilli
A growing body of epidemiological and toxicological evidence indicates that exposure to toxic elements (TEs), including As, Cd, Cr(VI), Pb, and Hg, is associated with a wide range of adverse health outcomes, including cancer, neurological and cardiovascular diseases. Given their widespread presence and toxicity, understanding the factors underlying inter-individual differences in susceptibility is essential, as not all exposed individuals develop the same health effects. Genetic variability, particularly single-nucleotide polymorphisms (SNPs), is increasingly recognized as a key determinant of individual responses to TE exposure. Variants in genes involved in metal transport, detoxification, and DNA repair, including DMT1, GSTP1, MT2A, hOGG1, and XRCC1, may influence internal dose and biological effects and have been proposed as potential susceptibility markers. However, current evidence remains inconsistent due to small sample sizes, heterogeneous exposure assessments, and limited considerations of ethnic diversity and gene–environment interactions. Future research should prioritize large and well-characterized populations integrating detailed exposure and lifestyle data. This review focuses on genetic susceptibility and gene–environment interactions in TE exposure, with particular emphasis on SNPs as key modulators of individual risk. It summarizes major toxic metals, reviews epidemiological evidence of the associated health risks, and highlights the role of genetic background in modulating TE-induced toxicity.

23 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MPMariangela Palazzo
Mariangela Palazzo
Andrea BorghiniAndrea Borghini
Andrea Borghini
Elisa BustaffaElisa Bustaffa
Elisa Bustaffa
SBSilvia Baldacci
Silvia Baldacci
Francesca GoriniFrancesca Gorini
Francesca Gorini
FMFabrizio Minichilli
Fabrizio Minichilli
Genetic variability is increasingly recognized as a key determinant of individual susceptibility to heavy metal-induced toxicity. Beyond exposure intensity and duration, inherited differences in genes regulating metal transport, detoxification, and DNA repair can substantially influence internal dose and biological response. To date, research has primarily focused on variants within these pathways, particularly single-nucleotide polymorphisms (SNPs), some of which have been proposed as potential susceptibility markers for toxic element (TE) toxicity. Despite these advances, current findings remain inconsistent. Many studies are limited by small sample sizes, heterogeneous exposure assessment, and insufficient consideration of ethnic-specific allelic diversity and gene-environment interactions. Future research should prioritize large, well-characterized, and ethnically diverse populations, integrating detailed exposure profiling, lifestyle factors, and co-exposures to more accurately define the genetic architecture underlying susceptibility. Therefore, in this review, we summarize the principal toxic metals, synthesize epidemiological evidence linking exposure to adverse health outcomes, and explore the contribution of genetic variability in modulating individual risk of metal-induced disease.

5 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
Francesca GoriniFrancesca Gorini
Francesca Gorini
Alessandro TonacciAlessandro Tonacci
Alessandro Tonacci
MPMariangela Palazzo
Mariangela Palazzo
Elisa BustaffaElisa Bustaffa
Elisa Bustaffa
FMFabrizio Minichilli
Fabrizio Minichilli
Andrea BorghiniAndrea Borghini
Andrea Borghini
Ischemic heart disease (IHD) is a chronic and progressive condition characterized by reduced blood flow, mainly due to atherosclerosis. It is currently the leading cause of mortality among cardiovascular diseases. In recent years, per- and polyfluoroalkyl substances (PFAS), a group of ubiquitous and highly persistent environmental contaminants, have emerged as potential risk factors for IHD. PFAS are well-established endocrine disruptors and have been associated with hypercholesterolemia, hypertriglyceridemia, and insulin resistance. Despite the limited number of epidemiological studies and inconsistent findings from occupational settings, accumulating evidence suggests that elevated exposure to certain PFAS compounds may increase the risk of IHD and vascular dysfunction, including processes related to atherosclerosis development, sometimes with dose–response relationships and sex-specific patterns. Mechanistic evidence supports this link, indicating that PFAS exposure induces molecular and cellular alterations relevant to cardiovascular pathophysiology, including increased oxidative stress and vascular inflammation, and disruption of lipid metabolism. In addition, PFAS may affect epigenetic regulation, telomere length, and mitochondrial DNA copy number, which are emerging biomarkers associated with atherosclerosis and IHD and may indicate early cardiovascular vulnerability. Future research integrating innovative approaches and advanced analytical techniques may help address current knowledge gaps and clarify the mechanistic pathways linking PFAS exposure to clinical cardiovascular outcomes.

24 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
Andrea BorghiniAndrea Borghini
Andrea Borghini
MPMariangela Palazzo
Mariangela Palazzo
Alessandro TonacciAlessandro Tonacci
Alessandro Tonacci
FMFabrizio Minichilli
Fabrizio Minichilli
HWHaotian Wu
Haotian Wu
Francesca GoriniFrancesca Gorini
Francesca Gorini
Micro- and nanoplastics (MPs/NPs) are ubiquitous environmental contaminants increasingly detected in air, food, drinking water, and human tissues, raising concerns about their potential long-term health effects. Accumulating evidence indicates that these particles can enter the human body, cross biological barriers, and elicit cellular and molecular responses relevant to disease development. This review synthesizes current mechanistic evidence linking MP/NP exposure to cardiovascular disease (CVD) and cancer, two leading global causes of morbidity and mortality that share interconnected pathogenic pathways. Key mechanisms include chronic inflammation, oxidative stress, gut microbiota dysbiosis, genotoxicity, and epigenetic alterations, all of which are widely implicated in both conditions. However, the available evidence is still largely derived from in vitro and animal studies, with limited human epidemiological data. Important uncertainties remain regarding real-world exposure characterization, dose–response relationships, and long-term clinical outcomes, underscoring the need for standardized analytical approaches, validated exposure and effect biomarkers, and large-scale longitudinal studies to clarify causal associations for both cancer and CVD. Taken together, current evidence suggests that MPs/NPs may represent emerging environmental contributors to shared pathogenic pathways linking CVD and cancer; however, establishing causality in humans will require well-designed longitudinal studies that integrate exposure assessment and clinical outcomes.

29 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MPMariangela Palazzo
Mariangela Palazzo
Francesca GoriniFrancesca Gorini
Francesca Gorini
LSLudovica Simonini
Ludovica Simonini
FMFabrizio Minichilli
Fabrizio Minichilli
Andrea BorghiniAndrea Borghini
Andrea Borghini
Environmental exposure to persistent and non-persistent endocrine-disrupting chemicals (EDCs), including per- and polyfluoroalkyl substances (PFAS), polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs), polycyclic aromatic hydrocarbons (PAHs), dioxins, phthalates, and bisphenols, has been increasingly associated with elevated cardiovascular disease (CVD) risk. Emerging evidence suggests the importance of gene–environment interactions in modulating individual susceptibility to EDC-related cardiovascular effects. This review summarizes current knowledge by synthesizing the main classes of EDCs, evaluating the evidence linking them to cardiovascular outcomes, and highlighting how genetic variability may modulate EDC-induced cardiovascular risk. Across the studies analyzed, the most extensively investigated genetic polymorphisms involve pathways related to oxidative stress regulation, xenobiotic metabolism and detoxification, hormone signaling, and lipid homeostasis. Variants in antioxidant defense genes, such as CAT, eNOS, and PON1, have been associated with increased hypertension risk and vascular dysfunction following exposure to bisphenols and PAHs. Polymorphisms in GSTP1, CYP2C19, ABCB1, and MTHFR may influence susceptibility to cardiometabolic alterations and congenital heart defects, whereas variants in ESR2, FTO, LEPR, and INSIG2 have been linked to obesity, dyslipidemia, and hypertension associated with PFAS, PBDEs, and bisphenols. A deeper understanding of gene–environment interactions is essential to advance preventive cardiology and mitigate the cardiovascular impact of environmental pollutants.